Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Hugh Cleland, CFA
Medwell Capital Corp.MWC.VCOMMENTJan 24, 2007
In phase 3 pivotal trial for secondary progressive MS and about a year away from getting data. Just got FDA approval to start trials in the US. Very high Risk and very high Reward.
Hugh Cleland, CFAOwned
$3.72
Stock price when the opinion was issued
Consumer Products
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
